Phase II Trial of Ibrutinib + Venetoclax in Previously Untreated, High-Risk Chronic Lymphocytic Leukemia (CLL)

December 1-4, 2018; San Diego, California
Ongoing combination therapy achieved improved responses, including in older patients and across all high-risk groups, with 96% and 69% of patients achieving CR/CRi and BM MRD negativity, respectively, at 18 months.
Format: Microsoft PowerPoint (.ppt)
File Size: 229 KB
Released: December 12, 2018

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower.
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Incyte
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Seagen
Takeda Oncology

Related Content

Downloadable slides on recent updates in R/R FL, with a focus on bispecific antibodies and CAR T-cell therapy, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Laurie H. Sehn, MD, MPH Released: February 2, 2023

Downloadable slides on recent updates in R/R FL, with a focus on second-line therapies and third-line epigenetic modifiers and PI3K inhibitors, from Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Laurie H. Sehn, MD, MPH Released: February 2, 2023

On-demand webcast from an ASH 2022 satellite symposium on BTK inhibitors for patients with CLL and MCL, from Clinical Care Options (CCO)

Jeff Sharman, MD
Program Director
Ian W. Flinn, MD, PhD Susan M. O'Brien, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 31, 2023 Expired: January 30, 2024

On-demand Clinical Care Options (CCO) webcast from a December 2022 symposium: experts discuss new care standards and evolving treatment strategies for aggressive B-cell lymphomas

John P. Leonard, MD
Program Director
John Allan, MD Laurie H. Sehn, MD, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 30, 2023 Expired: January 29, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings